| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.021 | 0.9 |